SUBJECT: Medical Logistics Guidance for the DoD Coronavirus Disease 2019 (COVID-19) Vaccination Program

References: See Enclosure 1

1. **PURPOSE.** This Defense Health Agency-Procedural Instruction (DHA-PI), based on the authority of References (a) and (b), and in accordance with the guidance of References (c) through (n), establishes the Defense Health Agency’s (DHA’s) procedures for ordering, receiving, and managing COVID-19 Vaccines inventory and ancillary kits.

2. **APPLICABILITY.** DHA, DHA components (activities under the authority, direction, and control of DHA), Military Departments (MILDEPs), Military Medical Treatment Facilities (MTFs), all personnel to include: assigned or attached Active Duty and Reserve members, federal civilians, member of the Commissioned Corps of the Public Health Service, contractors (when required by the terms of the applicable contract), and other personnel assigned temporary or permanent duties at DHA, to include DHA regional and field activities (remote locations), and subordinate organizations administered and managed by DHA, to include MTF under the authority, direction, and control of the DHA.

3. **POLICY IMPLEMENTATION.** It is DHA’s instruction, pursuant to References (a) through (m) that MTFs and DHA Components will follow procedures outlined in this DHA-PI.


5. **RESPONSIBILITIES.** See Enclosure 2.
6. **PROCEDURES.** See Enclosure 3.

7. **PROPOSENT AND WAIVERS.** The proponent of this publication is the Assistant Director (AD), Combat Support. When MTFs are unable to comply with this publication the MTF may request a waiver by providing justification that includes a full analysis of the expected benefits and must include a formal review by the MTF senior officer. The MTF senior leader will endorse the waiver request and forward them through their chain of command to the Director, DHA to determine if the waiver may be granted.

8. **RELEASABILITY. Cleared for public release.** This DHA-PI is available on the Internet from the Health.mil site at: https://health.mil/Reference-Center/Policies and is also available to authorized users from the DHA SharePoint site at: https://info.health.mil/cos/admin/pub/SitePages/Home.aspx.

9. **EFFECTIVE DATE.** This DHA-PI:

   a. Is effective upon signature.

   b. Will expire 10 years from the date of signature if it has not been reissued or cancelled before this date in accordance with Reference (c).

10. **FORMS**


    b. DHA Form 177, Potentially Compromised Temperature Sensitive Medical Products Worksheet is available at https://info.health.mil/cos/admin/DHA_Forms_Management/DHA_Forms1/DHA%20177.pdf.

/S/
RONALD J. PLACE
LTG, MC, USA
Director

Enclosures
1. References
2. Responsibilities
3. Procedures
ENCLOSURE 1

REFERENCES

(a) DoD Directive 5136.01, “Assistant Secretary of Defense for Health Affairs (ASD (HA)),” September 30, 2013, as amended
(c) DHA-Procedural Instruction 5025.01, “Publication System,” August 24, 2018
(d) DoD Instruction 6430.02, “Defense Medical Logistics Program,” August 23, 2017
(e) DHA-Procedural Instruction 6430.02, “Defense Medical Logistics (MEDLOG) Enterprise Activity (EA),” September 27, 2018
(f) Defense Logistics Agency Regulation 4145.21, “Preparation of Medical Temperature Sensitive Products Requiring Cold Chain Management for Shipment,” November 20, 2018
(g) U.S. Department of Health and Human Services, Centers for Disease Control (CDC) and Prevention, “Vaccine Storage and Handling Toolkit,” January 2019
(h) DHA-Guide “Vaccine Storage and Handling Guide,” August 2018, as amended
(i) DHA-Procedural Instruction 3700.01, “Director’s Critical Information Requirements (DCIRs), Situation Report (SITREP),” October 4, 2019, as amended
(j) U.S. Department of Health and Human Services, Centers for Disease Control (CDC) and Prevention, “COVID-19 Vaccination Program Interim Playbook for Jurisdiction Operations,” September 16, 2020¹
(k) U.S. Department of Health and Human Services, Centers for Disease Control (CDC) and Prevention, “Supplemental COVID-19 Vaccine Redistribution Agreement,” September 14, 2020
(l) U.S. Department of Health and Human Services, Centers for Disease Control (CDC) and Prevention, “Vaccine Storage and Handling Toolkit,” January 2020²
(m) USAMMA-DOC, “Vaccine Redistribution Standard Operating Procedures (SOP),” September 2019³

¹ This reference can be found at: https://www.cdc.gov/vaccines/imz-managers/downloads/COVID-19-Vaccination-Program-Interim_Playbook.pdf
² This reference can be found at: https://www.cdc.gov/vaccines/hcp/admin/storage/toolkit/index.html
³ This reference can be found at: https://www.usamma.army.mil/Pages/DOC-Home.aspx
ENCLOSURE 2

RESPONSIBILITIES

1. **DIRECTOR, DHA.** The Director, DHA, will assign the Chief, DHA Medical Logistics (MEDLOG) to implement this DHA-PI. DHA Director shall be responsible for coordination with MILDEPs and development of process for redistribution to MILDEPs.

2. **DHA, ADs.** The DHA, ADs must ensure military MTFs or DHA components implement and comply with this DHA-PI.

3. **DEPUTY ASSISTANT DIRECTOR, MEDLOG.** The Deputy Assistant Director, MEDLOG will perform oversight of the delivery of all MEDLOG business functions at DHA MTF or DHA Components in accordance with References (b) through (m).

4. **CHIEF, DHA MEDLOG.** Chief, DHA MEDLOG will ensure the procedures for this program are audit compliant.

5. **SECRETARIES OF THE MILDEPS.** The Secretaries of the MILDEPs must ensure MTFs under their command and control comply with the guidance in this publication.

6. **MTF DIRECTORS.** The MTF Directors must establish effective MEDLOG procedures to support and ensure adherence to ordering, receipting, and managing inventory of COVID-19 Vaccines guidelines included in this DHA-PI and must:
   
   a. Ensure Immunization and MEDLOG designate Points of Contacts (POCs) communicate the daily usage of COVID-19 Vaccines administered in order to track accurate movements and all inventory status changes of the vaccine in accordance with Operation Warp Speed (OWS) requirements.

   b. Ensure Temperature Monitoring Device systems are capable of monitoring storage locations 24 hours a day, 7 days a week, and notify the appropriate personnel when a failure is detected.

   c. Implement more stringent inspection and recording requirements than what is specified in this DHA-PI if appropriate.

   d. Ensure the Temperature Sensitive Medical Products (TSMP) Coordinator performs all tasks required in supporting this DHA-PI.
e. If an MTF is designated as an MTF Redistribution Hub, ensure COVID-19 Vaccine and ancillary kit(s) are handled in accordance with the manufacturer, Centers for Disease Control and Prevention (CDC), and U.S. Army Medical Materiel Agency Distributions Operations Center (USAMMA-DOC) guidance on COVID-19 Vaccine storage, shipping, and handling procedures.

f. If an MTF is designated as the MTF supported by an MTF Hub, ensure COVID-19 Vaccine and ancillary kit(s) are handled in accordance with the manufacturer, CDC, and USAMMA-DOC guidance on COVID-19 Vaccine storage, shipping, and handling procedures.

7. CHIEF, MTF MEDLOG. The Chief, MTF MEDLOG is responsible for all MEDLOG operations in the MTF or satellite MTF, and DHA Component to the extent authorized by the MTF Director. The Chief MTF, MEDLOG will act as the single point of contact for orchestrating effective and efficient supply chain support for MTFs or DHA Components. Additionally, the Chief MTF, MEDLOG must:

   a. Ensure all storage units are labeled properly.
   
   b. Ensure storage units are physically monitored per the guidelines of this DHA-PI.
   
   c. Ensure proper documentation of storage unit temperatures.
   
   
   e. Designate a MEDLOG POC to maintain the COVID-19 Vaccine on-hand balances within the COVID-19 Customer Owned Assemblage based on daily updates from the Immunization POC.
   
   f. If a MTF is designated as an MTF Redistribution Hub, ensure:

      (1) All material required for handling and redistributing COVID-19 Vaccine and ancillary kits are onsite prior to receiving the materials.

      (2) COVID-19 Vaccine and ancillary kit(s) are handled in accordance with the manufacturer, CDC, and USAMMA-DOC guidance on storage, shipping, and handling procedures.

8. ACCOUNTABLE MEDICAL SUPPLY OFFICER. The Accountable Medical Supply Officer must:

   a. Maintain the required storage temperatures, for materiel in medical logistics and have a calibrated working recording thermometer.
b. Follow CDC guidance: Avoid placing or storing any items other than vaccines, diluents, and water bottles inside storage units. If other medications and biological products must be stored in the same unit as vaccines, they must be clearly marked and stored in separate containers or bins from vaccines. Potentially contaminated items (e.g., blood, urine, stool) should be properly contained and stored below vaccines to avoid contamination from drips or leaks. For further guidance go to https://www.cdc.gov/vaccines/pubs/pinkbook/vac-storage.html.

c. Ensure to contact USAMMA DOC at usarmy.detrick.medcom-usamma.mbx.doc@mail.mil for Continental United States (CONUS) sites on product quality discrepancies/shortages within the COVID-19 ancillary kits, National Stock Number (NSN) 6515016923900 / 6515016923904. Outside Continental United States (OCONUS) and Fleet customers should contact Defense Logistics Agency (DLA) at dla.trpsptccc@dla.mil directly. Complete a Product Quality Deficiency Report for non-vaccines discrepancies and route to normal processing channels prior to or after contacting the appropriate POC.

d. Ensure personnel handling COVID-19 Vaccines and ancillary kits comply with all handling instructions from the manufacturer and federal guidelines.

e. Ensure all applicable guidance provided within this DHA-PI is followed.

9. TSMP COORDINATOR. The TSMP Coordinator has overall responsibility for monitoring the TSMP program at the MTF. The TSMP Coordinator must:

a. Ensure each freezer is labeled as “Freezer Ultralow -80° Celsius (C)” or “Freezer -20°C” and refrigerators labeled as “Refrigerator 2-8°C” and labeled for “COVID-19 Vaccine storage” on the outside of the unit.

b. Ensure COVID-19 Vaccine and ancillary kits’ storage unit temperatures are documented on the Temperature Log for each unit.

c. Ensure physical checks are performed at the beginning and end of each duty day for proper operation and temperature ranges of COVID-19 Vaccines storage units in accordance with manufactures’ guidance.

d. Ensure manufacturers’ required temperature parameters are strictly adhered to when transporting to outlying clinics.

e. Ensure all MTF or DHA component departments are following appropriate manufacturer, CDC, USAMMA-DOC, DLA and DHA guidance for COVID-19 Vaccines and ancillary kits.

f. Unless specifically prohibited by other DHA guidance, COVID-19 Vaccine storage and ancillary kit units must be connected to an emergency or backup power source to ensure proper storage conditions are maintained during commercial power interruption. Outlying clinics are an exception to the backup power source requirement.
10. OUTLYING CLINICS OFFICER IN CHARGE. The Clinic Officer in Charge is responsible for ensuring proper COVID-19 Vaccines and ancillary kits handling processes, procedures, and storage are adhered to while used at off-site clinics and other remote locations (away from the main MTF) such as a Soldier Readiness Processing site. To reduce potential losses at these sites, minimize on-hand materiel and return remaining TSMP to a properly monitored and alarmed storage area at the end of each duty day.
PROCEDURES

1. MTF COVID-19 PROCESS IN DMLSS

   a. The quantity of COVID-19 Vaccine and ancillary kits requested is based on the requirements for the MTF’s population at risk which has been vetted and consolidated at the DHA Immunization Health Division.

   b. The Service Vaccine Representative will submit weekly orders to DLA or to the USAMMA-DOC, based on that week’s vaccine allocations. The Service Vaccine Representative will coordinate with the MTF(s) on the allocation quantity to be received. The MTF(s) will add the assemblage and process an In-Shipment Gain (SHG) for the COVID-19 Vaccine and ancillary kits in the DMLSS AM Module.

   (1) Add the Customer Owned Assemblage in DMLSS AM Module.

      (a) Add the “COVID-19 Vaccine Response Program” (CVRP) Standard Assemblage for COVID-19 from the Select Assemblage table.

      (b) Associate to the appropriate Pharmacy or Clinic Customer and associated Expense Center to the CVRP Standard Assemblage. Upon completion, the COVID-19 Vaccine Catalog Record and ancillary kit record will be added to the MTF Catalog.

      (c) Add the Location and Sub Location to the Assemblage Record Data for the COVID-19 Vaccine and ancillary kits.

      (d) Perform an Item Allowance Change for the COVID-19 Vaccine and ancillary kits in the CVRP Standard Assemblage that matches the quantity of the materials in the order received by the MTF(s) MEDLOG Division. The MTF(s) MEDLOG Division will increase the allowance cumulatively in DMLSS AM to reflect the total quantity of vaccines and ancillary kits received at the MTF MEDLOG. As the second, third, or subsequent orders are received, the receipt quantity will be added to the current allowance quantity to equal the total product received to date. The allowance quantity will never decrease.

   (2) The MTF(s) MEDLOG Division will create additional individual CVRP Standard Assemblages to be added for MTF(s) with internal Customer Area Inventory Management customers utilizing COVID-19 vaccines and ancillary kits for vaccinations at outlying clinics where tracking is mandated. In the additional CVRP Standard Assemblages, MTF MEDLOG will update and standardize the following three fields to identify the outlying clinic.

      (a) The geographic location or name of the outlying clinic will be added in parenthesis after the defaulted “COVID-19 VACCINE RESPONSE PROGRAM” in the ‘Assemblage Description’ field.
(b) The ‘Build Control Number’ will be populated to match the geographic location or outlying clinic name.

(c) The ‘Warehouse Location’ will also be populated to match the geographic location or outlying clinic name.

(3) Gaining the COVID-19 Vaccine and ancillary kits to the CVRP Standard Assemblage in the DMLSS AM.

(a) Handle the COVID-19 Vaccine and ancillary kits in accordance with the manufacturer’s shipping and handling guidance and CDC’s guidance on COVID-19 Vaccine storage and handling guidance (i.e., CDC COVID-19 Vaccination Program Interim Playbook for Jurisdiction Operations, CDC Vaccine Storage and Handling Toolkit, and CDC Supplemental COVID-19 Vaccine Redistribution Agreement).

(b) Once any COVID-19 Vaccine and ancillary kit containers are opened and manufacturer guidance meticulously followed, Logistics will immediately contact DLA or contact USAMMA-DOC via (301) 619-4318/8002 or DSN 343-4318/8002 and provide:

1. Lot number
2. Quantity per lot
3. Expiration date
4. Status of monitor

(c) The MTF(s) MEDLOG Division will use the NSN which identifies the lowest unit of measure (LUM) which will be represented as each (EA) for vial and tracking of all variations of the Food and Drug Administration (FDA) approved COVID-19 Vaccines.

1. The Pfizer (NSN 6505016924172/National Drug Code (NDC) 59267100002) and Moderna (NSN 6505016925287/NDC 80777027399) COVID-19 Vaccine catalog records are sourced items that must be added to the MTF DMLSS Catalog in order to meet the daily reporting requirements of on-hand inventory at the vial level. Due to system logic, DMLSS Inventory Management is unable to track Quality Assurance (QA) information or provide unit of measure conversion data for non-stocked items of COVID 19 vaccines in order to meet OWS requirements. The vaccines are currently being procured as case (CA) for Pfizer (195 vials) and box (BX) for Moderna (10 vials).

2. To comply with the requirements of OWS to track the Pfizer (NSN 6505016924172) and Moderna (NSN 6505016925287) COVID-19 Vaccines at the lowest units of measure, it was determined that Pfizer (NSN 6505016924173/NDC 57267100001) and Moderna (NSN 6505016925286/NDC 80777027310) which are cataloged at the vial level with a unit of sale of each (EA) will be utilized. Within the CDC COVID-19 Vaccine Codes and Crosswalk table, the Pfizer NDC 59267100002 correlates to Pfizer NDC 59267100001 and the
Moderna NDC 80777027399 correlates to Moderna NDC 80777027310. There is a correlation of unit of sale to unit of use which can be viewed at https://www.cdc.gov/vaccines/programs/iis/code-sets.html.

Note: Due to the OWS requirement of tracking the vaccine by the LUM, the shipping document NSN/NDC will differ from the DMLSS AM inventory accounting NSN.

(d) MTF(s) must return the cold chain monitoring equipment to the manufacture per the shipment instructions.

(e) Execute a DMLSS AM SHG transactions into the DMLSS AM CVRP Standard Assemblage for COVID-19 Vaccine and ancillary kits. The MTF(s) MEDLOG Division will use the NSN which identify the lowest unit of measure represented as each (EA) for vial or kit (KT) and tracking of all variations of the FDA approved COVID-19 Vaccines.

1. The MTF MEDLOG Division will process a SHG for the COVID-19 Moderna ancillary kit NSN 6515016923900; one ancillary kit for every 10 Moderna COVID-19 Vaccines NSN 6505016925286 vials.

2. The MTF MEDLOG Division will process a SHG for the COVID-19 Pfizer ancillary kit NSN 6515016923904; one ancillary kit for every 195 Pfizer COVID-19 Vaccines NSN 6505016924173 vials.

(f) The MTF(s) MEDLOG Division will utilize the NSN provided to identify the unit of measure “KT” for the ancillary kit associated with the appropriate FDA approved vaccine.

(g) NDC numbers will not be used as Item Identifications for the COVID-19 Vaccines or COVID-19 ancillary kits in DMLSS AM.

(h) Input all Quality Assurance information to include the Manufacture, Manufacture Date, Expiration Date and Lot Number into the Assemblage Record Data for the COVID-19 Vaccine and ancillary kits in DMLSS AM.

Note: Upon receipt if any discrepancies are noted they will be reported to the Vaccine Service Representative and disposition determined.

(i) If DLA or USAMMA-DOC determine the COVID-19 Vaccine or ancillary kit is unserviceable, the product will be restratified and placed in a Suspended status within the CVRP Standard Assemblage for COVID-19 in the DMLSS AM Module. USAMMA-DOC questions or concerns will be directed to usarmy.detrick.medcom-usamma.mbx.vaccines@mail.mil. DLA questions and concerns will be directed to DSCPColdchain@dlamil or paacoldchain@dlamil.

(4) Decrementing the COVID-19 Vaccine and ancillary kits from the CVRP Standard Assemblage in the DMLSS AM Module.
Note: In Accordance with the Inventory Management Requirements of OWS, on-hand balances in the CVRP Standard Assemblage will be reported and decremented daily for the quantities of COVID-19 Vaccine vials and ancillary kits administered that day.

(a) The Customer or POC associated to the CVRP Standard Assemblage will provide a daily update to Logistics by 1500 hours local time via email of how much COVID-19 Vaccine and ancillary kits were administered in the Unit of Sale Quantity as opposed to the doses administered to include manufacturer and specific lot number(s).

(b) Logistics POC will decrement the applicable on-hand quantity based upon the daily notification provided by the customer or POC associated to the COVID-19 Vaccine and ancillary kits from the appropriate assemblage in the unit of sale quantity via the Out-Shipment Loss (SHL) Transaction. Air Force MEDLOG will perform an Issue Non-Routine (INR).

(c) The MTF MEDLOG Division will process a SHL daily for the decrement of on-hand balances of COVID-19 Moderna ancillary kit NSN 6515016923900; decrement one ancillary kit for every 10 Moderna COVID-19 Vaccines NSN 6505016925286 vials consumed. Air Force MEDLOG will perform an INR.

(d) The MTF MEDLOG Division will process a SHL daily for the COVID-19 Pfizer ancillary kit NSN 6515016923904; decrement one ancillary kit for every 195 Pfizer COVID-19 Vaccines NSN 6505016924173 vials consumed. Air Force MTF(s) MEDLOG will perform an INR.

3. REDISTRIBUTING THE -80° FROZEN COVID-19 VACCINE. Redistribute the -80° frozen COVID-19 Vaccine and associated ancillary kits in the DMLSS AM Module CVRP Standard Assemblage from the MTF Redistribution Hub in accordance with USAMMA-DOC, manufacturer, and CDC guidance on COVID-19 Vaccine storage, shipping and handling (e.g., CDC COVID-19 Vaccination Program Interim Playbook for Jurisdiction Operations).

Note: DHA headquarters will designate specific MTFs the Redistribution Hubs which will redistribute the -80° frozen COVID-19 Vaccine and associated ancillary kits to other MTFs without ultra-cold storage capabilities; USAMMA-DOC is the Release Authority which will provide approval notification, guidance, and shipping materials to the MTF Redistribution Hub.

a. The MTF Redistribution Hub will:

(1) Receive USAMMA-DOC approval and guidance to redistribute -80° frozen COVID-19 Vaccine and associated ancillary kits to the Supported MTF(s). USAMMA-DOC will provide the MTF Hub with the approved shipping containers and temptation needed for each shipment.

(3) Execute the Service appropriate transaction below for the -80° frozen COVID-19 Vaccine and ancillary kits, and print the DD Form 1348-1A, Issue Release/Receipt Document.

(a) Air Force will utilize the INR transaction.

(b) All others services will utilize the SHL transaction.

(4) Provide advance shipping information to USAMMA-DOC and the Supported MTF MEDLOG.

(5) Ship or transport the -80° frozen COVID-19 Vaccine and ancillary kits, and the DD Form 1348-1A to the supported MTF with all Quality Control information adhering to USAMMA-DOC, manufacturer, and CDC requirements.

b. The Supported MTF will:

(1) Coordinate with USAMMA-DOC and the MTF Redistribution Hub and provide:

(a) The Ship-To address and POC.

(b) Commercial (e.g., FEDEX) shipping account.

(2) Upon receipt of the -80° frozen COVID-19 Vaccine and ancillary kit, will execute a DMLSS AM SHG Transaction into the CVRP Standard Assemblage and follow all applicable guidance under paragraph 2 of this enclosure.

(3) Input all Quality Control information for the -80° frozen COVID-19 Vaccine and ancillary kits into the DMLSS AM CVRP Standard Assemblage Records.

4. REDISTRIBUTION OF THE MODERN MODERN MODERNA COVID-19 VACCINE

a. Redistribution of Moderna Vaccine outside the designated redistribution hubs is highly discouraged based on CDC guidance relating to shipping protocols.

b. Designated Theater Lead Agent for Medical Materiel that have been identified as redistribution hubs for OCONUS activities; must coordinate with DLA during the redistribution process. CONUS activities will coordinate with USAMMA-DOC for the redistribution process.

c. Moderna can only be redistributed at -25°C to -15°C. The vibrations at 2°C to 8°C during shipments will cause the vaccine to breakdown and lose potency. CDC recommends that each site administering vaccine receive a direct shipment. Moderna can be stored at 2°C to 8°C for 30 days. Once thawed, the vaccine cannot be re-frozen.

d. To determine the Moderna COVID-19 Vaccine expiration date, providers can scan the quick response (QR) code (two-dimensional matrix barcode) located on the vial or carton or
access the manufacturer’s website at https://www.modernatx.com/covid19vaccine-eua/providers/vial-lookup#vialLookUpTool and enter the lot number. The expiration date will be displayed. CDC’s COVID-19 vaccine expiration date tracking tool website at https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/expiration-tracker.pdf can help providers keep track of the expiration date by lot number.

e. The following precautions must be adhered to if a MTF must transport thawed COVID-19 Vaccines between clinics:

   (1) Punctured vials should not be transported.

   (2) Ensure vaccine does not re-freeze during transport.

   (3) Vaccine must be protected as much as possible from drops, shocks, and vibration whether in the carton, vial, case, or cooler.

   (4) Vaccine should be transported in the original shipping container/carton.

   (5) If transport must be conducted at the vial level, the vial should be placed with dunnage (padding material like bubble wrap or similar padding) to minimize movement during transport.

   (6) The vaccine should always be transported in insulated containers qualified to maintain 2°C to 8°C for the duration of transport.

   (7) The transport containers must be secured when being transported to prevent unnecessary movement.

   (8) After completion of transport, vaccine should immediately be placed into a vaccine storage unit at 2°C to 8°C.

   (9) Vaccine should only be transported one time and should not be transported back again to the point of origin or to a new location.

5. MANAGE POTENTIALLY COMPROMISED COVID-19 VACCINES AND ANCILLARY KITS POST-RECEIPT

   a. All MTF or DHA components and supported activities will complete a Director’s Critical Information Requirements per Reference (i) and submit any updates to DHA-AD CS-Med Log-BusinessOps.

   b. Ensure COVID-19 Vaccine and ancillary kits are maintained in a working storage unit at proper temperature.
c. Label compromised COVID-19 Vaccine and/or ancillary kits as “DO NOT USE,” and place in a separate container apart from other products in the storage unit.

d. Complete DHA Form 177, Potentially Compromised TSMP Worksheet and submit completed worksheet and all supporting documentation to the appropriate source of supply, USAMMA-DOC or DLA Troop Support Medical.

e. DO NOT destroy, discard, or use COVID-19 vaccines or ancillary kits until released by the USAMMA-DOC and/or DLA. Comply with all disposition instructions from USAMMA-DOC and/or DLA for compromised COVID-19 material. If the USAMMA-DOC or DLA disposition determination is that the COVID-19 Vaccine and/or ancillary kits is unserviceable and directs the MTF to destroy, the MTF will follow the Destruction Process.

6. DESTRUCTION PROCESS

a. MTF will work with the Source of Supply for proper disposition instructions when the COVID-19 Vaccine and/or ancillary kit is deemed unserviceable.

b. The MTF will follow local regulatory procedures for destruction of COVID-19 materials using DMLSS AM destruction process.

c. The MTF will create and maintain destruction document, DD Form 1348-1A.
## GLOSSARY

### ABBREVIATIONS AND ACRONYMS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AD</td>
<td>Assistant Director</td>
</tr>
<tr>
<td>AM</td>
<td>Assemblage Management</td>
</tr>
<tr>
<td>C</td>
<td>Celsius</td>
</tr>
<tr>
<td>CDC</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>CONUS</td>
<td>Continental United States</td>
</tr>
<tr>
<td>COVID-19</td>
<td>Coronavirus Disease 2019</td>
</tr>
<tr>
<td>CVRP</td>
<td>COVID-19 Vaccine Response Program</td>
</tr>
<tr>
<td>DHA</td>
<td>Defense Health Agency</td>
</tr>
<tr>
<td>DLA</td>
<td>Defense Logistics Agency</td>
</tr>
<tr>
<td>DMLSS</td>
<td>Defense Medical Logistics Standard Support</td>
</tr>
<tr>
<td>EA</td>
<td>each</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>INR</td>
<td>Issue Non-Routine</td>
</tr>
<tr>
<td>LUM</td>
<td>Lowest Unit of Measure</td>
</tr>
<tr>
<td>MEDLOG</td>
<td>Medical Logistics</td>
</tr>
<tr>
<td>MILDEPS</td>
<td>Military Departments</td>
</tr>
<tr>
<td>MTF</td>
<td>Military Medical Treatment Facility</td>
</tr>
<tr>
<td>NSN</td>
<td>National Stock Number</td>
</tr>
<tr>
<td>NDC</td>
<td>National Drug Code</td>
</tr>
<tr>
<td>OCONUS</td>
<td>Outside Continental United States</td>
</tr>
<tr>
<td>OWS</td>
<td>Operation Warp Speed</td>
</tr>
<tr>
<td>POC</td>
<td>Point of Contact</td>
</tr>
<tr>
<td>SHG</td>
<td>In-Shipement Gain</td>
</tr>
<tr>
<td>SHL</td>
<td>Out-Shipement Loss</td>
</tr>
<tr>
<td>TSMP</td>
<td>Temperature Sensitive Medical Products</td>
</tr>
<tr>
<td>USAMMA-DOC</td>
<td>U.S. Army Medical Materiel Agency Distributions Operations Center</td>
</tr>
</tbody>
</table>